GVB Biopharma Takes Control as Industry Leader in Cannabis

Business by 2FIRSTS.ai

Jan.04.2024

GVB Biopharma Takes Control as Industry Leader in Cannabis

Leading industrial hemp and cannabis industry company, GVB Biopharma, announced its return to private ownership effective December 28, 2023.

According to a report by the United States Press Agency on January 3rd, leading industrial hemp and cannabis industry enterprise GVB Biopharma announced that as of December 28, 2023, the company will be under the leadership of its founding team once again.

GVB Biopharma has consistently been at the forefront of the industry with its cutting-edge low-temperature cannabis extraction, refinement, conversion, and advanced product formulation technologies. As a leading supplier of cannabinoids, GVB Biopharma is committed to maintaining the reputation of its high-quality and highly regarded products. The company has successfully reverted to being a privately-owned entity, allowing it to be more flexible in adapting to the changes in the global cannabis market in the future.

Chief Executive Officer Drew Spiegel has expressed, "As the cannabis industry continues to mature, our vision and capabilities align perfectly with market trends. Under our commitment to quality, innovation, and esteemed clientele, we are thrilled to be at the forefront of the next phase of industry growth.

References:

[1] GVB Biopharma Taken Private, Poised for Continued Growth in Hemp and Cannabis Industry

Also Read:

[1] Argentinian National Gendarmerie Discovers 5-Ton Marijuana Haul

[2] 22nd Century Group Announces Completion of Cannabis Business Sale

#North America #United States #CBD #E-cigarette Industry #Tobacco Control Plan #Cannabis vaporization

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Bangladesh High Court Questions Legality of BEZA’s Approval for Philip Morris Nicotine Pouch Factory

The High Court in Bangladesh has asked government bodies to explain why the approval granted to Philip Morris to establish a nicotine pouch factory should not be deemed illegal. Petitioners argue the decision contradicts existing policies and a 2016 Appellate Division ruling that restricts new tobacco-related enterprises. Authorities have ten days to respond.

Nov.20 by 2FIRSTS.ai

South Korea’s Parliament Reconsiders Bill to Regulate Synthetic Nicotine as Tobacco

South Korea’s National Assembly is once again reviewing a bill to classify synthetic nicotine as a tobacco product under the Tobacco Business Act. The proposal aims to close regulatory loopholes that allow untaxed, unregulated nicotine liquids — often used by minors — to circulate freely. Lawmakers expect the bill to pass during the current session amid growing public and civic pressure.

Nov.26 by 2FIRSTS.ai

U.S. Lawmakers Seek to Empower HHS to Destroy Counterfeit Chinese Tobacco Products

Bipartisan members of the U.S. Congress have introduced the “Ensuring the Necessary Destruction of Illicit Chinese Tobacco Act” (END Act), seeking to amend the Federal Food, Drug, and Cosmetic Act to authorize the Department of Health and Human Services (HHS) to directly destroy adulterated, misbranded, or counterfeit imported tobacco products.Major tobacco companies, including Altria, along with several public health organizations, have announced their support for the bill.

Nov.11 by 2FIRSTS.ai

BAT Podcast with AACS CEO: Vape Policy Imbalance Fuels Australia’s Billion-Dollar Illicit Market

In BAT’s The Smokeless Word podcast, AACS CEO Theo Foukkare warned that high taxes and strict vape bans have fueled Australia’s AUD 10-billion illicit nicotine market and rising retail crime, urging urgent regulatory reform.